Want to see GB:OPTI full AI Analyst Report?
Top Page
OptiBiotix Health
(LSE:OPTI)
Select Model
Select Model
Rating:49Neutral
Price Target:
7.00 p
▲(23.89% Upside)
Action:Reiterated
Date:09/11/26
The score is held back primarily by weak financial quality—ongoing losses and cash burn despite strong revenue growth—while the no-debt balance sheet helps. Technically, momentum is positive but looks overheated (RSI ~90), and valuation is constrained by negative earnings and no stated dividend yield.
Positive Factors
Patented IP and partner-led model
A portfolio of patented strains and formulations gives OptiBiotix differentiated intellectual property that can be licensed across multiple health categories and territories. Partner-led commercialisation may broaden distribution without requiring the company to build a large consumer brand operation itself.
Negative Factors
Material and widening losses
OptiBiotix has not yet converted its revenue growth into sustainable profitability, with the latest net loss widening and operating losses remaining substantial. Persistent losses can limit internal investment capacity and increase reliance on external funding while the commercial model scales.
Read all positive and negative factors
Positive Factors
Negative Factors
Patented IP and partner-led model
A portfolio of patented strains and formulations gives OptiBiotix differentiated intellectual property that can be licensed across multiple health categories and territories. Partner-led commercialisation may broaden distribution without requiring the company to build a large consumer brand operation itself.
Read all positive factors
OptiBiotix Health (OPTI) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£6.56M
Dividend YieldN/A
Average Volume (3M)154.50K
Price to Earnings (P/E)―
Beta (1Y)0.47
Revenue Growth34.02%
EPS Growth-93.85%
CountryUK
Employees9
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.04
Shares Outstanding103,300,300
10 Day Avg. Volume197,765
30 Day Avg. Volume154,501
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.09
Price to Sales (P/S)5.86
P/FCF Ratio-3.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
OptiBiotix Health Business Overview & Revenue Model
Company Description
OptiBiotix Health Plc, a life sciences enterprise headquartered in York, United Kingdom, specializes in the discovery and advancement of microbiome-modulating technologies. The company formulates distinct microbial strains, innovative compounds, a...
How the Company Makes Money
OptiBiotix primarily makes money by commercialising its probiotic and microbiome-related intellectual property through business-to-business arrangements rather than operating as a large-scale consumer brand owner. Key revenue streams include: (1) ...
OptiBiotix Health Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
63
Positive
Cash Flow
27
Negative
| Breakdown | Dec 2025 | Jun 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.17M | 870.00K | 644.00K | 457.00K | 2.21M |
| Gross Profit | 614.00K | 331.00K | 320.00K | 244.00K | 1.12M |
| EBITDA | -2.93M | -2.06M | -1.84M | 2.75M | 6.51M |
| Net Income | -3.89M | -1.80M | -2.04M | 2.59M | 6.26M |
Balance Sheet | |||||
| Total Assets | 6.89M | 9.04M | 9.40M | 11.55M | 20.14M |
| Cash, Cash Equivalents and Short-Term Investments | 1.04M | 739.00K | 635.00K | 1.05M | 2.01M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 819.36K |
| Total Liabilities | 610.00K | 647.00K | 532.00K | 643.00K | 1.97M |
| Stockholders Equity | 6.28M | 8.40M | 8.87M | 10.90M | 18.14M |
Cash Flow | |||||
| Free Cash Flow | -1.77M | -1.77M | -1.53M | -1.28M | -1.76M |
| Operating Cash Flow | -1.77M | -1.77M | -1.53M | -1.11M | -1.56M |
| Investing Cash Flow | 1.35M | 587.00K | 1.11M | -331.00K | -193.51K |
| Financing Cash Flow | 713.00K | 1.28M | 0.00 | 485.00K | 2.90M |
OptiBiotix Health Technical Analysis
Positive
5.65
Price Trends
5.86
Positive
5.82
Positive
6.14
Positive
Market Momentum
0.11
Negative
65.87
Neutral
76.56
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:OPTI, the sentiment is Positive. The current price of 5.65 is below the 20-day moving average (MA) of 5.79, below the 50-day MA of 5.86, and below the 200-day MA of 6.14, indicating a bullish trend. The MACD of 0.11 indicates Negative momentum. The RSI at 65.87 is Neutral, neither overbought nor oversold. The STOCH value of 76.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:OPTI.
OptiBiotix Health Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | £23.97M | -51.39 | -5.25% | ― | 95.16% | 85.60% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | £5.05M | -1.68 | -37.30% | ― | ― | 85.56% | |
49 Neutral | £6.56M | -1.68 | -52.92% | ― | 34.02% | -93.85% | |
45 Neutral | £4.31M | -3.50 | -83.53% | ― | ― | 93.02% | |
42 Neutral | £1.59M | -0.40 | -152.41% | ― | -70.77% | 60.39% | |
41 Neutral | £6.37M | -8.82 | 104.99% | ― | ― | 69.64% |
* Healthcare Sector Average
GB:OPTI
OptiBiotix Health
6.35
-3.90
-38.05%
GB:TCF
Evgen Pharma
0.19
-0.07
-26.00%
GB:FUM
Futura Medical
0.25
-8.59
-97.18%
GB:NFX
Nuformix Plc
0.17
0.05
43.48%
GB:CIZ
Cizzle Biotechnology Holdings PLC
1.50
-0.20
-11.76%
GB:SBTX
SkinBioTherapeutics
9.25
-7.00
-43.08%
OptiBiotix Health Corporate Events
Business Operations and StrategyProduct-Related Announcements
OptiBiotix advances SweetBiotix sugar substitute toward commercial production
Positive
Sep 8, 2026
OptiBiotix Health has provided an update on its SweetBiotix range, a portfolio of sweet fibres designed to act as healthy sugar substitutes while supporting gut health. The business aims to leverage these microbiome-focused sweeteners to capture d...
Business Operations and StrategyProduct-Related Announcements
OptiBiotix Taps GLP-1 Boom With Holland & Barrett FORMI Launch
Positive
Sep 2, 2026
OptiBiotix Health has expanded its presence in the weight management segment through the launch of Holland Barrett’s new FORMI Weight Loss Complex, which contains its clinically validated SlimBiome formulation. The product, sold as raspberr...
Business Operations and StrategyProduct-Related Announcements
OptiBiotix to brief investors after SweetBiotix sampling success
Positive
Jun 26, 2026
OptiBiotix Health will host a live investor presentation and QA on 2 July 2026 via its Investor Hub, following successful SweetBiotix sampling on 24 June. Chief executive Stephen O’Hara will update investors on the commercial progress of fir...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.